Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [823]

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide...

Dr Martin McCabe- University of Manchester, Manchester, England

$Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Martin McCabe- University of Manchester, Manchester, England )$

Outcomes of clinico-radiologically advanced cancer (cT4b) of buccal mucosa: A...

Dr Prateek Jain - Tata Medical Center, Kolkata, India

Outcomes of clinico-radiologically advanced cancer (cT4b) of buccal mucosa: A retrospective analysis of 104 patients ( Dr Prateek Jain - Tata Medical Center, Kolkata, India )

War in Ukraine: Impacts on the Ukrainian cancer care system

Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine

War in Ukraine: Impacts on the Ukrainian cancer care system ( Dr Andriy Hrynkiv - Lviv Regional Cancer Centre of Ukraine, Lviv, Ukraine )

War in Ukraine: Current and future impacts on the Romanian cancer care system

Dr Nicoleta Antone - The Institute of Oncology, Cluj-Napoca, Romania

War in Ukraine: Current and future impacts on the Romanian cancer care system ( Dr Nicoleta Antone - The Institute of Oncology, Cluj-Napoca, Romania )

International Society of Paediatric Surgical Oncology (IPSO) surgical practice...

Dr Jaime Shalkow - National Institute of Paediatrics, Mexico City, Mexico

International Society of Paediatric Surgical Oncology (IPSO) surgical practice guidelines ( Dr Jaime Shalkow - National Institute of Paediatrics, Mexico City, Mexico )

More from ecancer